Trial: 201809005

A phase II study of dose-dense gemcitabine plus cisplatin (ddGC) in patients with muscle-invasive bladder cancer with bladder preservation for those patients whose tumors harbor deleterious DNA damage response (DDR) gene alterations

Phase

II

Principal Investigator

Knoche, Eric

Disease Site

Urinary Bladder

Learn more about this study at: clinicaltrials.gov